Submit your email to push it up the queue
Janssen Inc., a subsidiary of Johnson & Johnson, is a leading pharmaceutical company headquartered in California. Established in 1953, Janssen has made significant strides in the healthcare industry, focusing on innovative solutions across various therapeutic areas, including oncology, immunology, and neuroscience. With a strong presence in North America and Europe, Janssen is renowned for its commitment to research and development, delivering groundbreaking medications that address unmet medical needs. Core products such as Stelara and Imbruvica exemplify the company's dedication to advancing patient care through unique mechanisms of action and robust clinical evidence. Janssen's market position is bolstered by its continuous investment in cutting-edge science and strategic partnerships, solidifying its reputation as a trusted leader in the pharmaceutical sector.
How does Janssen Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Janssen Inc.'s score of 78 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Janssen Inc., headquartered in California, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Johnson & Johnson, and any climate commitments or emissions data would be inherited from its parent organisation. Janssen Inc. aligns with Johnson & Johnson's sustainability initiatives, which include various climate commitments and reduction targets. However, specific reduction targets or achievements for Janssen Inc. are not detailed in the available information. The company participates in industry-standard initiatives such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and RE100, all of which are cascaded from Johnson & Johnson. As part of its corporate family, Janssen Inc. is expected to adhere to the overarching climate strategies set by Johnson & Johnson, which focus on reducing greenhouse gas emissions across all scopes. However, without specific data or targets for Janssen Inc. itself, the details remain vague.
Access structured emissions data, company-specific emission factors, and source documents
1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Janssen Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.